Exact Mass: 493.30393680000003
Exact Mass Matches: 493.30393680000003
Found 500 metabolites which its exact mass value is equals to given mass value 493.30393680000003
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Tiamulin
C28H47NO4S (493.32256220000005)
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic Same as: D06127 CONFIDENCE standard compound; INTERNAL_ID 1055
Syringolin A
A syrbactin that has a (3E,9E)-2,7-dioxo-1,6-diazacyclododeca-3,9-diene skeleton that is substituted by an isopropyl group at position 5 and by a [(2S)-2-({[(1S)-1-carboxy-2-methylpropyl]carbamoyl}amino)-3-methylbutanoyl]nitrilo group at the 8-pro-S position. It is produced by the pathogenic bacterium Pseudomonas syringae pv. syringae.
Imatinib
Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
LysoPC(16:1(9Z)/0:0)
LysoPC(16:1(9Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(16:1(9Z)), in particular, consists of one chain of palmitoleic acid at the C-1 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(16:1(9Z)/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(16:1(9Z)/0:0), in particular, consists of one chain of palmitoleic acid at the C-1 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.
Cytochalasin Npho
Cytochalasin Npho is a mycotoxin from Phomopsis sp Mycotoxin from Phomopsis species
(5Z)-7-[(1R,2R,5S)-5-Hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine
C27H43NO7 (493.30393680000003)
(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Chenodeoxycholylthreonine
Chenodeoxycholylthreonine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylthreonine consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Threonine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylthreonine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylthreonine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Deoxycholylthreonine
Deoxycholylthreonine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylthreonine consists of the bile acid deoxycholic acid conjugated to the amino acid Threonine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylthreonine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylthreonine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
1-(9Z-Nonadecenoyl)-glycero-3-phosphoethanolamine
(2R)-2-{[(9Z)-Hexadec-9-enoyl]oxy}-3-hydroxypropyl 2-(trimethylazaniumyl)ethyl phosphate
4-[[2-Methyl-2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]propanoyl]amino]adamantane-1-carboxamide
C25H34F3N5O2 (493.26644600000003)
[(2R,3S,4S,6R,7S,8R)-4-Ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[2-(diethylamino)ethylsulfanyl]acetate
C28H47NO4S (493.32256220000005)
Glycolipids
C24H50N2O6P+ (493.34063100000003)
Glycolipids is practically insoluble (in water) and a moderately acidic compound (based on its pKa). Glycolipids can be found in chayote, chinese mustard, swamp cabbage, and winter squash, which makes glycolipids a potential biomarker for the consumption of these food products. Glycolipids are lipids with a carbohydrate attached by a glycosidic bond. Their role is to maintain the stability of the cell membrane and to facilitate cellular recognition, which is crucial to the immune response and in the connections that allow cells to connect to one another to form tissues. Glycolipids are found on the surface of all eukaryotic cell membranes, where they extend from the phospholipid bilayer into the extracellular environment .
Vinylamycin
C26H43N3O6 (493.31516980000004)
A 15-membered cyclodepsipeptide isolated from Streptomyces sp.M1982-63F1. It exhibits moderate activity against Gram-positive bacteria.
INDANOMYCIN
C31H43NO4 (493.31919180000006)
An indene that is (3aS,7aR)-2,3,3a,4,5,7a-hexahydro-1H-indene which is substituted at the 2-pro-R position by a 1H-pyrrol-2-ylcarbonyl group, at the 9-pro-S position by an ethyl group, and at the 5-pro-R position by a hexa-1,3-dineyl group in which position 4 has been substituted by a (2R,3S,6R)-6-[(1R)-1-carboxyethyl]-3-methyltetrahydropyran-2-yl group. It exhibits activity against Gram-positive bacteria as well as antihypertensive and antitumour. It also functions as an effective growth promoter for ruminants.
Imatinib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EA - Bcr-abl tyrosine kinase inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor COVID info from Guide to PHARMACOLOGY, clinicaltrial, clinicaltrials, clinical trial, clinical trials C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163999 - cKIT-targeting Agent C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C159198 - c-KIT Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C155700 - BCR-ABL Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors D000970 - Antineoplastic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 2742 INTERNAL_ID 2742; CONFIDENCE standard compound CONFIDENCE standard compound; INTERNAL_ID 8521 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3633
C28H35N3O5_(1R,5R,7S,12R)-12-Hydroxy-4,4,4,4,12,14-hexamethyl-4H,13H-spiro[9,14-diazatetracyclo[5.5.2.0~1,9~.0~3,7~]tetradecane-5,8-[1,4]dioxepino[2,3-g]indole]-9,13(10H)-dione
C28H35N3O5 (493.25765800000005)
Ala Phe Arg Thr
C22H35N7O6 (493.26486900000003)
Ala Phe Thr Arg
C22H35N7O6 (493.26486900000003)
Ala Ile Lys Tyr
Ala Ile Tyr Lys
Ala Lys Ile Tyr
Ala Lys Leu Tyr
Ala Lys Tyr Ile
Ala Lys Tyr Leu
Ala Leu Lys Tyr
Ala Leu Tyr Lys
Ala Arg Phe Thr
C22H35N7O6 (493.26486900000003)
Ala Arg Thr Phe
C22H35N7O6 (493.26486900000003)
Ala Thr Phe Arg
C22H35N7O6 (493.26486900000003)
Ala Thr Arg Phe
C22H35N7O6 (493.26486900000003)
Ala Tyr Ile Lys
Ala Tyr Lys Ile
Ala Tyr Lys Leu
Ala Tyr Leu Lys
Phe Ala Arg Thr
C22H35N7O6 (493.26486900000003)
Phe Ala Thr Arg
C22H35N7O6 (493.26486900000003)
Phe Ile Lys Ser
Phe Ile Ser Lys
Phe Lys Ile Ser
Phe Lys Leu Ser
Phe Lys Ser Ile
Phe Lys Ser Leu
Phe Lys Thr Val
Phe Lys Val Thr
Phe Leu Lys Ser
Phe Leu Ser Lys
Phe Arg Ala Thr
C22H35N7O6 (493.26486900000003)
Phe Arg Thr Ala
C22H35N7O6 (493.26486900000003)
Phe Ser Ile Lys
Phe Ser Lys Ile
Phe Ser Lys Leu
Phe Ser Leu Lys
Phe Thr Ala Arg
C22H35N7O6 (493.26486900000003)
Phe Thr Lys Val
Phe Thr Arg Ala
C22H35N7O6 (493.26486900000003)
Phe Thr Val Lys
Phe Val Lys Thr
Phe Val Thr Lys
Gly Arg Val Tyr
C22H35N7O6 (493.26486900000003)
Gly Arg Tyr Val
C22H35N7O6 (493.26486900000003)
Gly Val Arg Tyr
C22H35N7O6 (493.26486900000003)
Gly Val Tyr Arg
C22H35N7O6 (493.26486900000003)
Gly Tyr Arg Val
C22H35N7O6 (493.26486900000003)
Gly Tyr Val Arg
C22H35N7O6 (493.26486900000003)
His Ile Lys Pro
His Ile Pro Lys
His Ile Pro Gln
C22H35N7O6 (493.26486900000003)
His Ile Gln Pro
C22H35N7O6 (493.26486900000003)
His Lys Ile Pro
His Lys Leu Pro
His Lys Pro Ile
His Lys Pro Leu
His Leu Lys Pro
His Leu Pro Lys
His Leu Pro Gln
C22H35N7O6 (493.26486900000003)
His Leu Gln Pro
C22H35N7O6 (493.26486900000003)
His Pro Ile Lys
His Pro Ile Gln
C22H35N7O6 (493.26486900000003)
His Pro Lys Ile
His Pro Lys Leu
His Pro Leu Lys
His Pro Leu Gln
C22H35N7O6 (493.26486900000003)
His Pro Gln Ile
C22H35N7O6 (493.26486900000003)
His Pro Gln Leu
C22H35N7O6 (493.26486900000003)
His Gln Ile Pro
C22H35N7O6 (493.26486900000003)
His Gln Leu Pro
C22H35N7O6 (493.26486900000003)
His Gln Pro Ile
C22H35N7O6 (493.26486900000003)
His Gln Pro Leu
C22H35N7O6 (493.26486900000003)
Ile Ala Lys Tyr
Ile Ala Tyr Lys
Ile Phe Lys Ser
Ile Phe Ser Lys
Ile His Lys Pro
Ile His Pro Lys
Ile His Pro Gln
C22H35N7O6 (493.26486900000003)
Ile His Gln Pro
C22H35N7O6 (493.26486900000003)
Ile Lys Ala Tyr
Ile Lys Phe Ser
Ile Lys His Pro
Ile Lys Pro His
Ile Lys Ser Phe
Ile Lys Tyr Ala
Ile Pro His Lys
Ile Pro His Gln
C22H35N7O6 (493.26486900000003)
Ile Pro Lys His
Ile Pro Gln His
C22H35N7O6 (493.26486900000003)
Ile Gln His Pro
C22H35N7O6 (493.26486900000003)
Ile Gln Pro His
C22H35N7O6 (493.26486900000003)
Ile Ser Phe Lys
Ile Ser Lys Phe
Ile Tyr Ala Lys
Ile Tyr Lys Ala
Lys Ala Ile Tyr
Lys Ala Leu Tyr
Lys Ala Tyr Ile
Lys Ala Tyr Leu
Lys Phe Ile Ser
Lys Phe Leu Ser
Lys Phe Ser Ile
Lys Phe Ser Leu
Lys Phe Thr Val
Lys Phe Val Thr
Lys His Ile Pro
Lys His Leu Pro
Lys His Pro Ile
Lys His Pro Leu
Lys Ile Ala Tyr
Lys Ile Phe Ser
Lys Ile His Pro
Lys Ile Pro His
Lys Ile Ser Phe
Lys Ile Tyr Ala
Lys Leu Ala Tyr
Lys Leu Phe Ser
Lys Leu His Pro
Lys Leu Pro His
Lys Leu Ser Phe
Lys Leu Tyr Ala
Lys Pro His Ile
Lys Pro His Leu
Lys Pro Ile His
Lys Pro Leu His
Lys Ser Phe Ile
Lys Ser Phe Leu
Lys Ser Ile Phe
Lys Ser Leu Phe
Lys Thr Phe Val
Lys Thr Val Phe
Lys Val Phe Thr
Lys Val Thr Phe
Lys Tyr Ala Ile
Lys Tyr Ala Leu
Lys Tyr Ile Ala
Lys Tyr Leu Ala
Leu Ala Lys Tyr
Leu Ala Tyr Lys
Leu Phe Lys Ser
Leu Phe Ser Lys
Leu His Lys Pro
Leu His Pro Lys
Leu His Pro Gln
C22H35N7O6 (493.26486900000003)
Leu His Gln Pro
C22H35N7O6 (493.26486900000003)
Leu Lys Ala Tyr
Leu Lys Phe Ser
Leu Lys His Pro
Leu Lys Pro His
Leu Lys Ser Phe
Leu Lys Tyr Ala
Leu Pro His Lys
Leu Pro His Gln
C22H35N7O6 (493.26486900000003)
Leu Pro Lys His
Leu Pro Gln His
C22H35N7O6 (493.26486900000003)
Leu Gln His Pro
C22H35N7O6 (493.26486900000003)
Leu Gln Pro His
C22H35N7O6 (493.26486900000003)
Leu Ser Phe Lys
Leu Ser Lys Phe
Leu Tyr Ala Lys
Leu Tyr Lys Ala
Pro His Ile Lys
Pro His Ile Gln
C22H35N7O6 (493.26486900000003)
Pro His Lys Ile
Pro His Lys Leu
Pro His Leu Lys
Pro His Leu Gln
C22H35N7O6 (493.26486900000003)
Pro His Gln Ile
C22H35N7O6 (493.26486900000003)
Pro His Gln Leu
C22H35N7O6 (493.26486900000003)
Pro Ile His Lys
Pro Ile His Gln
C22H35N7O6 (493.26486900000003)
Pro Ile Lys His
Pro Ile Gln His
C22H35N7O6 (493.26486900000003)
Pro Lys His Ile
Pro Lys His Leu
Pro Lys Ile His
Pro Lys Leu His
Pro Leu His Lys
Pro Leu His Gln
C22H35N7O6 (493.26486900000003)
Pro Leu Lys His
Pro Leu Gln His
C22H35N7O6 (493.26486900000003)
Pro Gln His Ile
C22H35N7O6 (493.26486900000003)
Pro Gln His Leu
C22H35N7O6 (493.26486900000003)
Pro Gln Ile His
C22H35N7O6 (493.26486900000003)
Pro Gln Leu His
C22H35N7O6 (493.26486900000003)
Gln His Ile Pro
C22H35N7O6 (493.26486900000003)
Gln His Leu Pro
C22H35N7O6 (493.26486900000003)
Gln His Pro Ile
C22H35N7O6 (493.26486900000003)
Gln His Pro Leu
C22H35N7O6 (493.26486900000003)
Gln Ile His Pro
C22H35N7O6 (493.26486900000003)
Gln Ile Pro His
C22H35N7O6 (493.26486900000003)
Gln Leu His Pro
C22H35N7O6 (493.26486900000003)
Gln Leu Pro His
C22H35N7O6 (493.26486900000003)
Gln Pro His Ile
C22H35N7O6 (493.26486900000003)
Gln Pro His Leu
C22H35N7O6 (493.26486900000003)
Gln Pro Ile His
C22H35N7O6 (493.26486900000003)
Gln Pro Leu His
C22H35N7O6 (493.26486900000003)
Arg Ala Phe Thr
C22H35N7O6 (493.26486900000003)
Arg Ala Thr Phe
C22H35N7O6 (493.26486900000003)
Arg Phe Ala Thr
C22H35N7O6 (493.26486900000003)
Arg Phe Thr Ala
C22H35N7O6 (493.26486900000003)
Arg Gly Val Tyr
C22H35N7O6 (493.26486900000003)
Arg Gly Tyr Val
C22H35N7O6 (493.26486900000003)
Arg Thr Ala Phe
C22H35N7O6 (493.26486900000003)
Arg Thr Phe Ala
C22H35N7O6 (493.26486900000003)
Arg Val Gly Tyr
C22H35N7O6 (493.26486900000003)
Arg Val Tyr Gly
C22H35N7O6 (493.26486900000003)
Arg Tyr Gly Val
C22H35N7O6 (493.26486900000003)
Arg Tyr Val Gly
C22H35N7O6 (493.26486900000003)
Ser Phe Ile Lys
Ser Phe Lys Ile
Ser Phe Lys Leu
Ser Phe Leu Lys
Ser Ile Phe Lys
Ser Ile Lys Phe
Ser Lys Phe Ile
Ser Lys Phe Leu
Ser Lys Ile Phe
Ser Lys Leu Phe
Ser Leu Phe Lys
Ser Leu Lys Phe
Thr Ala Phe Arg
C22H35N7O6 (493.26486900000003)
Thr Ala Arg Phe
C22H35N7O6 (493.26486900000003)
Thr Phe Ala Arg
C22H35N7O6 (493.26486900000003)
Thr Phe Lys Val
Thr Phe Arg Ala
C22H35N7O6 (493.26486900000003)
Thr Phe Val Lys
Thr Lys Phe Val
Thr Lys Val Phe
Thr Arg Ala Phe
C22H35N7O6 (493.26486900000003)
Thr Arg Phe Ala
C22H35N7O6 (493.26486900000003)
Thr Val Phe Lys
Thr Val Lys Phe
Val Phe Lys Thr
Val Phe Thr Lys
Val Gly Arg Tyr
C22H35N7O6 (493.26486900000003)
Val Gly Tyr Arg
C22H35N7O6 (493.26486900000003)
Val Lys Phe Thr
Val Lys Thr Phe
Val Arg Gly Tyr
C22H35N7O6 (493.26486900000003)
Val Arg Tyr Gly
C22H35N7O6 (493.26486900000003)
Val Thr Phe Lys
Val Thr Lys Phe
Val Tyr Gly Arg
C22H35N7O6 (493.26486900000003)
Val Tyr Arg Gly
C22H35N7O6 (493.26486900000003)
Tyr Ala Ile Lys
Tyr Ala Lys Ile
Tyr Ala Lys Leu
Tyr Ala Leu Lys
Tyr Gly Arg Val
C22H35N7O6 (493.26486900000003)
Tyr Gly Val Arg
C22H35N7O6 (493.26486900000003)
Tyr Ile Ala Lys
Tyr Ile Lys Ala
Tyr Lys Ala Ile
Tyr Lys Ala Leu
Tyr Lys Ile Ala
Tyr Lys Leu Ala
Tyr Leu Ala Lys
Tyr Leu Lys Ala
Tyr Arg Gly Val
C22H35N7O6 (493.26486900000003)
Tyr Arg Val Gly
C22H35N7O6 (493.26486900000003)
Tyr Val Gly Arg
C22H35N7O6 (493.26486900000003)
Tyr Val Arg Gly
C22H35N7O6 (493.26486900000003)
PC(16:1/0:0)
PC(16:1/0:0)[U]
LysoPC(16:1/0:0)
Cytochalasin Npho
1-[(9E)-hexadecenoyl]-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 16:1 in which the 1-acyl group is (9E)-hexadecenoyl.
[2-[(E)-hexadec-9-enoyl]oxy-3-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(5Z)-7-[(1R,2R,5S)-5-Hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine
C27H43NO7 (493.30393680000003)
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (E)-nonadec-9-enoate
[3-[(E)-hexadec-9-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(2R)-2-{[(9Z)-Hexadec-9-enoyl]oxy}-3-hydroxypropyl 2-(trimethylazaniumyl)ethyl phosphate
(2R)-N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(1R,9S,10S,11S)-12-[2-(dimethylamino)acetyl]-10-(hydroxymethyl)-11-(4-methylpiperazine-1-carbonyl)-5-phenyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
C27H35N5O4 (493.26889100000005)
(2R)-N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2R)-N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2S)-N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2R)-N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2S)-N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2S)-N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
(2R,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-8-[2-(3-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
C29H36FN3O3 (493.27405580000004)
N-[(4S,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(5R,6R,9S)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C28H35N3O5 (493.25765800000005)
N-[(5R,6S,9R)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C28H35N3O5 (493.25765800000005)
(2S)-N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2R)-N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
methyl N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C28H35N3O5 (493.25765800000005)
1-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
C28H35N3O5 (493.25765800000005)
1-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
C28H35N3O5 (493.25765800000005)
methyl N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C28H35N3O5 (493.25765800000005)
N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
1-[[(4R,5R)-8-(1-cyclohexenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methyl-3-propylurea
C25H39N3O5S (493.26102840000004)
N-[(4R,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4S,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4S,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4S,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(5R,6R,9R)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C28H35N3O5 (493.25765800000005)
N-[(5S,6S,9S)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C28H35N3O5 (493.25765800000005)
N-[(5S,6S,9R)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C28H35N3O5 (493.25765800000005)
N-[(5S,6R,9S)-8-[cyclopropyl(oxo)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide
C28H35N3O5 (493.25765800000005)
(2S)-N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
methyl N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C28H35N3O5 (493.25765800000005)
methyl N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C28H35N3O5 (493.25765800000005)
methyl N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11,16-dimethyl-14-oxo-9-oxa-13,16-diazatetracyclo[13.7.0.02,7.017,22]docosa-1(15),2,4,6,17,19,21-heptaen-10-yl]methyl]-N-methylcarbamate
C28H35N3O5 (493.25765800000005)
1-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
C28H35N3O5 (493.25765800000005)
1-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
C28H35N3O5 (493.25765800000005)
1-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
C28H35N3O5 (493.25765800000005)
1-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3,6-dihydro-2H-pyran-3-yl]-3-(2-methoxyphenyl)urea
C28H35N3O5 (493.25765800000005)
(1S,9R,10R,11R)-12-[2-(dimethylamino)acetyl]-10-(hydroxymethyl)-11-(4-methylpiperazine-1-carbonyl)-5-phenyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
C27H35N5O4 (493.26889100000005)
(2R)-N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2S)-N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2R)-N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
N-[(2S,3S,4R)-3,4-dihydroxy-15-methyl-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadecan-2-yl]formamide
C24H47NO9 (493.32506520000004)
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-nonadec-9-enoate
[2-propanoyloxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
3-Hydroxy-2-(2-hydroxytetradecanoylamino)undecane-1-sulfonic acid
C25H51NO6S (493.34369060000006)
3-Hydroxy-2-(2-hydroxypentadecanoylamino)decane-1-sulfonic acid
C25H51NO6S (493.34369060000006)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] acetate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] butanoate
3-Hydroxy-2-(2-hydroxytridecanoylamino)dodecane-1-sulfonic acid
C25H51NO6S (493.34369060000006)
3-Hydroxy-2-(2-hydroxydodecanoylamino)tridecane-1-sulfonic acid
C25H51NO6S (493.34369060000006)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] hexanoate
[3-[(Z)-hexadec-9-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[hydroxy-[(E)-3-hydroxy-2-(octanoylamino)undec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
[2-acetyloxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-acetyloxy-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C23H44NO8P (493.28043940000003)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] propanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] pentanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] (Z)-tetradec-9-enoate
C23H44NO8P (493.28043940000003)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-pentadec-9-enoate
C23H44NO8P (493.28043940000003)
[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-hexadec-9-enoate
C23H44NO8P (493.28043940000003)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-tridec-9-enoate
C23H44NO8P (493.28043940000003)
[(2R)-3-[(E)-hexadec-7-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)hexadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[[(E)-2-acetamido-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[hydroxy-[(E)-3-hydroxy-2-(pentanoylamino)tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[[(E)-2-(butanoylamino)-3-hydroxypentadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[hydroxy-[(E)-3-hydroxy-2-(undecanoylamino)oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[[(E)-2-(heptanoylamino)-3-hydroxydodec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[[(E)-2-(decanoylamino)-3-hydroxynon-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[[(E)-2-(hexanoylamino)-3-hydroxytridec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
2-[hydroxy-[(E)-3-hydroxy-2-(nonanoylamino)dec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C24H50N2O6P+ (493.34063100000003)
1-[(9Z)-hexadecenoyl]-sn-glycero-3-phosphocholine
A 1-O-acyl-sn-glycero-3-phosphocholine in which the 1-acyl group is (9Z)-hexadecenoyl (palmitoleoyl).
2-(3-(1-(((4E,10E)-2,9-Dioxo-12-isopropyl-1,8-diazacyclododecane-4,10-diene-3-yl)carbamoyl)-2-methylpropyl)ureido)-3-methylbutyric acid
2-[(9Z)-hexadecenoyl]-sn-glycero-3-phosphocholine
A lysophosphatidylcholine(0:0/16:1) in which the 2-acyl group is specified as (9Z)-hexadecenoyl.
[(9Z)-hexadecenoyl]-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 16:1 in which the acyl group is specified as (9Z)-hexadecenoyl and is located at either position 1 or 2.
lysophosphatidylcholine 16:1
An lysophosphatidylcholine in which the acyl group is hexadecenoyl (position of double bond not specified). If R1 is hexadecenoyl and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is hexadecenoyl then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.
lysophosphatidylcholine(0:0/16:1)
A 2-acyl-sn-glycero-3-phosphocholine in which the 2-acyl group contains 16 carbons and 1 double bond.
Lysophosphatidylcholine(16:1/0:0)
A 1-acyl-sn-glycero-3-phosphocholine in which the 1-acyl group contains 16 carbons and 1 double bond.
phosphatidylethanolamine 18:1 zwitterion
C23H44NO8P (493.28043940000003)
A 1,2-diacyl-sn-glycero-3-phosphoethanolamine zwitterion in which the two acyl groups contain a total of 18 carbons and 1 double bond.
phosphatidylcholine 15:1
C23H44NO8P (493.28043940000003)
A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl groups contain a total of 15 carbons and 1 double bond.
lysophosphatidylcholine (16:1/0:0)
A lysophosphatidylcholine 16:1 in which the acyl group is located at position 1.
PC(15:1)
C23H44NO8P (493.28043940000003)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(17:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PC(16:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
5,8,13-trihydroxy-14-(1-hydroxy-4-methyldecan-3-yl)-3-isopropyl-6-methyl-11-methylidene-1-oxa-4,7,12-triazacyclotetradeca-4,7,9,12-tetraen-2-one
C26H43N3O6 (493.31516980000004)
14-ethyl-2,6-dihydroxy-4,19-dimethoxy-16-methyl-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosan-21-yl acetate
(2r)-2-[(5s,6r)-6-[(3e,5e)-6-[(1s,4s,5r)-1-ethyl-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid
C31H43NO4 (493.31919180000006)
(1r,2s,3s,4s,5s,6r,8r,12r,13r,16r,19s,20s,21r)-14-ethyl-4,6,19,21-tetramethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane
C27H43NO7 (493.30393680000003)